PharmDr. Ondřej Holas, Ph.D.

Born: December 10, 1983 in Hradec Králové, Czech Republic

Current position:
Assistant Professor in the Group of Molecular and Clinical Pharmacotherapy, Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Králové, Charles University

Contact information

  • Work address: Heyrovského 1203, 500 05, Hradec Králové, Czech Republic
  • Email:
  • Tel.: +420 495 067 412
  • ORCID ID: 0000-0002-8335-0123
  • Research ID: AAD-8633-2019
  • Scopus Author ID: 14622671800


Research interests:

  • Advanced nano-drug-delivery systems based on biocompatible and biodegradable materials.
  • Design and development of targeted drug delivery systems for nuclear receptor ligands and nucleic acids.
  • Study of nanomaterials immunogenicity.
  • Molecular modeling of novel orphan receptors ligands.
  • Advanced methods of computational chemistry, computer aided drug design.

Education and Empoyment:

  • 2015                Assistant professor, Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Králové, Charles University
  • 2012-2015      TEAB project, Faculty of Pharmacy in Hradec Králové, Charles University
  • 2008-2012      Ph.D. studies, Department of Pharmaceutical Chemistry and Analysis, Faculty of Pharmacy in Hradec Králové, Charles University in Prague

Teaching activities:

  • From 2016      Lectures, Physical Principles of Dosage Forms (Guarantor of the subject)
  • From 2015      Lectures and practical classes, Pharmaceutical Technology
  • From 2015      Lectures, Modern Trends in Drug Development
  • Supervisor of: 16 finalized diploma theses, 8 finalized doctor theses, 3 researched PhD theses, 1 finalized PhD thesis

Research grants (member of a team):

  • 2017-2019: Standard project, Czech Science Foundation.  Dynamics of nuclear receptor-mediated gene regulation: implement for the understanding ofdetoxification functions and optimization of therapy GAČR 17-06841S,
  • 2019-2021: Standard project, Czech Science Foundation. Novel interventions for the treatment of triglycerides, cholesterol and bile acids diseases with human CAR ligands. 19-14497S
  • 2019-2021: Standard project, Czech Science Foundation. Novel interventions for the treatment of triglycerides, cholesterol and bile acids diseases with human CAR ligands. 19-14497S
  • 2019-2021: Technology Agency of the Czech Republic, Development of a new dosage form for oral administration of vaccines. FV40365
  • Grant Agency of the Charles University projects (3 times)


  • Horizon 2020 COST action - The European Network on Understanding Gastrointestinal Absorption-related Processes (UNGAP

International experience:

  • 2015    Faculty of Pharmacy, Commenius University in Bratislava
  • 2013    4 months, Sotriffer Group (Prof. Christoph Sotriffer), Institute of Pharmacy and Food Chemistry, Julius Maximilians University, Würzburg
  • 2009    1 month, Institute for Medical Research and Occupational Health, Zagreb

Czech and international collaboration:

  • Josef Masek, Veterinary and research institute in Brno
  • Anette Müllertz, Department of Pharmaceutics & Analytical Chemistry, The Faculty of Pharmaceutical Sciences (FARMA), University of Copenhagen, Denmark
  • Daniel Scherman, Unité de Technologies Chimiques et Biologiques pour la Santé, Paris Descartes, CPSC


  • 2008    Prize of Penta company for the best thesis.
  • 2008    2nd place award at International Student’s Scientific conference.

Selected publications:

47 papers in international journals

H-index: 20 (WoS), 900+ citation

  1. Vranikova, B.; Svacinova, P; Marushka, J.; Brokesova, J.; Holas, O.; Tebbens, J.D.; Sklubalova, Z. The importance of the coating material type and amount in the preparation of liquisolid systems based on magnesium aluminometasilicate carrier, Eur. J. Pharm. Sci. 2021, 165, 105952. IF2020=4.384 (Q2)
  2. Kubackova, J.; Holas, O.*; Zbytovska, J.; Vranikova, B.; Zeng, G.; Pavek, P.; Mullertz, A. Oligonucleotide Delivery across the Caco-2 Monolayer: The Design and Evaluation of Self-Emulsifying Drug Delivery Systems (SEDDS), Pharmaceutics, 2021, 13, 459. IF2020=4.421 (Q2)
  3. Boltnarova, B.; Kubackova.; Skoda, J.; Stefela, A.; Smekalova, M.; Svacinova, P.; Pavkova, I.; Dittrich, M.; Scherman, D.; Zbytovska, J.; Pavek, P.; Holas, O.* PLGA Based Nanospheres as a Potent Macrophage-Specific Drug Delivery System, Nanomaterials, 2021, 11, 749. IF2019=4.324 (Q2)
  4. Stefela, A.; Kaspar, M.; Drastik, M.; Holas, O.; Hroch, M.; Smutny, T.; Skoda, J.; Hutnikova, M.; Pandey, A.V.; Micuda, S.; Kudova, E.; Pavek, P.; 3β-Isoobeticholic acid efficiently activates the farnesoid X receptor (FXR) due to its epimerization to 3α-epimer by hepatic metabolism, J. Steroid. Biochem. Mol. Biol. 2020, 202, 105702. IF2019=3.813 (Q2)
  5. Kubackova, J.; Zbytovska, J.; Holas, O.* Nanomaterials for direct and indirect immunomodulation: A review of applications. Eur. J. Pharm. Sci. 2019, Article Number: 105139, IF2019=3.532 (Q2)
  6. Snejdrova, E.; Podzimek, S.; Martiska, J.; Holas, O.; Dittrich, M. Branched PLGA derivatives with tailored drug delivery properties. Acta Pharm. 2020, 70, 63-75. IF2018=1.451 (Q4)
  7. Dusek, J.; Skoda, J. ; Holas, O.; Horvatova, A.; Smutny, T.; Linhartova, L.; Hirsova, P.; T.; Kucera, O.; Micuda, S.; Braeuning,; A. Pavek, P.; Stilbene compound trans-3,4,5,4 '-tetramethoxystilbene, a potential anticancer drug, regulates constitutive androstane receptor (Car) target genes, but does not possess proliferative activity in mouse liver. Toxicol. Lett. 2019, 313, 1-10. IF2018=3.499 (Q1)
  8. Carazo, A.; Dusek, J.; Holas, O.; Skoda, J.; Hyrsova, L.; Smutny, T.; Soukup, T.; Dosedel, M.; Pavek, P.; Teriflunomide Is an Indirect Human Constitutive Androstane Receptor (CAR) Activator Interacting with Epidermal Growth Factor (EGF) Signaling. Frontiers Pharmacol. 2018, 9, 993. IF2017=3.831 (Q1)
  9. Knebbel, C.; Neeb, J.; Zahn, E.; Schmidt, F.; Carazo, A.; Holas, O.; Pavek, P.; Puschel, G.P.; Zanger, U.M.; Sussmuth, R.; Lampen, A.; Marx-Stoeling, P.; Brauening, A. Unexpected Effects of Propiconazole, Tebuconazole, and Their Mixture on the Receptors CAR and PXR in Human Liver Cells. Toxicol. Sci. 2018, 163, 170-181. IF2017=4.181 (Q1)
  10. Holas, O.;*, Ondrejcek, P.; Dolezal, M.; Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors as potential antituberculotics: development in the past decade. J. Enz. Inhib. Med. Chem. 2015, 30, 629-648. IF=5.051

© Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 500 03 Hradec Králové, Czech Republic
Website information | Powered by Kentico